Haleon Business Summary

Haleon plc (HLN) operates as a global leader in the consumer healthcare sector, generating revenue through the large-scale manufacturing and retail distribution of over-the-counter (OTC) medicines, oral care products, and wellness supplements. The company’s revenue is diversified across six primary business segments: Oral Health (e.g., Sensodyne, Parodontax), Pain Relief (e.g., Advil, Panadol), Digestive Health (e.g., Nexium, Tums), Vitamins, Minerals and Supplements (e.g., Centrum), Respiratory Health (e.g., Theraflu), and Therapeutic Skin Health. As of early 2026, Haleon has transitioned to a more agile operating model featuring six regional units: North America, Europe, Latin America, Middle East & Africa, India Subcontinent, and Asia Pacific. Its primary direct competitors include Kenvue, Procter & Gamble, Unilever, and Reckitt Benckiser; Haleon maintains a dominant market position as the world’s largest standalone consumer health specialist, leveraging a portfolio where over 70% of brands consistently maintain or gain global market share. The company is led by Chief Executive Officer Brian McNamara, who previously headed GSK’s consumer healthcare division and oversaw Haleon’s landmark 2022 demerger from GSK and Pfizer. The executive team includes Chief Financial Officer Dawn Allen, formerly of Tate & Lyle and Mars Inc., and recently appointed Chief Growth and Chief Transformation Officers tasked with executing the "Win as One" strategy. Governance is overseen by Chair Vindi Banga, who assumed the role on January 1, 2026, supported by Senior Independent Director Alan Stewart. Haleon’s pedigree is rooted in its origins as a joint venture between GSK and Pfizer, and it remains a high-conviction holding for major institutional investors, maintaining a board composed of seasoned veterans from the FMCG and pharmaceutical industries.